Raymond James upgraded shares of Eupraxia Pharmaceuticals (NASDAQ:EPRX – Free Report) to a strong-buy rating in a report published on Wednesday morning, Zacks.com reports.
Eupraxia Pharmaceuticals Price Performance
Shares of EPRX opened at $2.85 on Wednesday. Eupraxia Pharmaceuticals has a 12-month low of $2.48 and a 12-month high of $6.78.
Eupraxia Pharmaceuticals (NASDAQ:EPRX – Get Free Report) last announced its quarterly earnings data on Wednesday, May 8th. The company reported ($0.21) earnings per share for the quarter.
Eupraxia Pharmaceuticals Company Profile
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company’s lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.
Recommended Stories
- Five stocks we like better than Eupraxia Pharmaceuticals
- The 3 Best Retail Stocks to Shop for in August
- MarketBeat Week in Review – 5/20 – 5/24
- What Are Dividends? Buy the Best Dividend Stocks
- NASDAQ 100 vs. NASDAQ Composite: A Detailed Breakdown of NASDAQ
- Technology Stocks Explained: Here’s What to Know About Tech
- These 2 Retail Traders Favorites are Nearing Major Breakouts
Receive News & Ratings for Eupraxia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eupraxia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
